Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NTLA

Intellia Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for NTLA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.34

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:42 UTC.

What Intellia Therapeutics, Inc. does

Intellia Therapeutics is a biopharmaceutical company developing treatments using CRISPR gene editing and related technologies to address severe diseases. The company's lead product candidates are lonvoguran ziclumeran for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis, both in Phase 3 clinical development and designed to be administered as single intravenous infusions. Intellia plans to launch lonvoguran ziclumeran commercially in the first half of 2027 and is building commercial infrastructure to support potential product approvals.

Summarized from Intellia Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.34

Revenue, margins & earnings

FY2021: net loss $268M on revenue $33M$33MFY2021FY2022: net loss $474M on revenue $52M$52MFY2022FY2023: net loss $481M on revenue $36M$36MFY2023FY2024: net loss $519M on revenue $58M$58MFY2024FY2025: net loss $413M on revenue $68M$68MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-06
  • 2026-10-06VP, Chief Accounting OfficerSale-1,864$23.2K
  • 2026-08-24President and CEOSale-2,785$36.2K
  • 2026-08-24President and CEOSale-19,890$250.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics is a biopharmaceutical company developing treatments using CRISPR gene editing and related technologies to address severe diseases.

When did NTLA last file with the SEC?

Intellia Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-09-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:42 UTC. This page is also available as JSON at /api/data?ticker=NTLA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NTLA and 5,000+ tickers.

Create a free account — keep NTLA
For your agent
GET /api/data?ticker=NTLA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt